The company’s lead candidate program AST-004 is a novel small molecule candidate currently in human Phase I clinical safety trials with an intravenous injection formulation suitable for administration by emergency professionals. An oral “field” formulation of AST-004 for mild TBI and concussions, and for chronic administration for neurodegenerative diseases is in preclinical development.

In preclinical models of stroke and blunt trauma, AST-004 reduces early brain damage by selectively enhancing mitochondrial energy production in Astrocyte cells, the brain’s ‘natural caretakers’. AST-004 is being developed for Acute Ischemic Stroke, Severe TBI, and Alzheimer’s Disease. A follow on candidate is being developed for pain/migraine.

Pre-Series B Bridge Round

• Dreavant Capital
• Alzheimer's Drug Discovery Foundation
  
  Total: $25M USD raised

Preparing to initiate a Phase 2 clinical trial for its lead program, AST-004, for acute ischemic stroke.

Small molecules

Neurology